New targeted therapy trial offers hope for women with Tough-to-Treat uterine cancer
NCT ID NCT04251416
Summary
This study is testing an experimental drug called sacituzumab govitecan (IMMU-132) for women whose endometrial cancer has returned or continued growing despite prior chemotherapy. The drug is designed to deliver chemotherapy directly to cancer cells. Researchers will measure how well tumors shrink, how long patients live without their cancer worsening, and what side effects occur.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Smilow Cancer Hospital at Yale New Haven
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.